Caleb Alexander, MD, co-director of the Johns Hopkins School of Public Health Center for Drug Safety and Effectiveness in Baltimore. ... educated about the risks and benefits and if you can effectively monitor for safety.
When meeting with Rep. Earl Blumenauer (D-OR), Ms. Blank and ACP Resident/Fellow Member Joel Burnett, MD, led discussions on prescription drug pricing and physician workforce issues. ... I don't have any problems with that,” although the downside is
But at this point, he noted, the drug remains costly for many patients. ... Food and Drug Administration. FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate
FDA Drug Safety Communication. FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. ... Accessed on Sept. 14, 2016. FDA Drug Safety Communication. FDA revises warning regarding use of
with the drug are likely to outweigh its potential risks for each patient. ... Approved on the fast track as an orphan drug, safety and efficacy were evaluated in 4 clinical trials including 547 treated patients.
A labeling update and drug safety communication on low-molecular-weight heparin, including enoxaparin, regarding the risk of spinal column bleeding and subsequent paralysis after spinal injections, including epidural procedures and ... Safety and
dose should exceed 16 mg, according to the agency's drug safety communication online. ... The FDA is continuing to evaluate multiple sources of data in the ongoing safety review of this issue but has not changed its recommendations regarding the drug.
Rutgers University in Newark, N.J., and president of BLCMD Associates LLC in Chapel Hill, N.C., which offers consulting services in drug safety. ... Indeed, in the November 2011 Drug Safety, researchers published a study examining the prescription data
It's also recommended that clinicians discontinue the drug in patients with symptoms of liver injury. ... A drug safety communication about the risk of name confusion between ado-trastuzumab emtansine (Kadcyla) and trastuzumab (Herceptin).
A warning about drug interactions between boceprevir (Victrelis) and ritonavir-boosted HIV protease inhibitor drugs. ... However, the FDA continues to believe that the cardiovascular benefits of statins outweigh these small increased risks, according to